Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Actavis Acquires Furiex Pharmaceuticals

July 2, 2014 3:28 pm | News | Comments

Actavis announced that its subsidiary Forest Laboratories has successfully completed its acquisition of Furiex Pharmaceuticals in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval. Read more...

TOPICS:

Some 500 Genes Differ in Bipolar Patients’ Neurons

July 2, 2014 3:16 pm | by Cynthia Fox, Science Editor | Articles | Comments

Neurons of patients with bipolar disorder (BP) differ from the norm in a “striking” 500 or so genes, according to preliminary data generated using the Nobel-Prize-winning iPSC (induced pluripotent stem cell) approach, by Salk Institute neuroscientist Fred Gage. Read more...

TOPICS:

“Extensive” Errors Prompt Retraction of Stem Cell Claim

July 2, 2014 3:06 pm | by Malcolm Ritter, AP Science Writer | News | Comments

Scientists who reported that they'd found a startlingly simple way to make stem cells withdrew that claim Wednesday, admitting to "extensive" errors in the research that meant "we are unable to say without a doubt" that the method works. Read more...

TOPICS:
Advertisement

New Reprogramming Method Makes Better Stem Cells

July 2, 2014 1:07 pm | News | Comments

A team of researchers from the University of California, San Diego School of Medicine, Oregon Health & Science University and Salk Institute for Biological Studies has shown for the first time that stem cells created using different methods produce differing cells. Read more...

TOPICS:

RNA Reprogramming Technology for Generates Virus-free iPSCs

July 2, 2014 1:03 pm | EMD Millipore | Product Releases | Comments

Simplicon RNA Reprogramming Technology from EMD Millipore uses synthetic self-replicating RNA to create large numbers of human induced pluripotent stem cells (iPSCs) using a single transfection step. Read more...

TOPICS:

Safe, Efficient Concentration of Biological Samples

July 2, 2014 11:04 am | Product Releases | Comments

The miVac DNA is a compact concentrator from Genevac capable of safely and efficiently removing water and organic solvents from biological samples in a variety of formats including tubes, microplates and vials. Read more...

TOPICS:

Pfizer Receives Kosher Certification for Gaucher Disease Drug

July 2, 2014 10:55 am | News | Comments

Pfizer Inc. announced that the Orthodox Union has granted kosher certification to Elelyso (taliglucerase alfa) for injection, an enzyme replacement therapy for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease. Read more...

TOPICS:

Isis Earns $1M from GSK for Advancing Hep B Program

July 2, 2014 10:49 am | News | Comments

Isis Pharmaceuticals Inc. announced that it has earned a $1 million payment from GlaxoSmithKline related to the advancement of its program to develop antisense drugs to treat hepatitis B virus, a serious health problem that can lead to significant and potentially fatal health conditions. Read more...

TOPICS:
Advertisement

Common Element of Ancient Origin Controls Na, Ca Cellular Gates

July 2, 2014 10:43 am | News | Comments

Researchers at Johns Hopkins have spotted a strong family trait in two distant relatives: The channels that permit entry of sodium and calcium ions into cells - both of which are critical to life - turn out to share similar means for regulating ion intake, they say. Read more...

TOPICS:

Lung Cancer Alliance Commends NCI for SCLC Scientific Framework

July 2, 2014 10:32 am | News | Comments

The National Cancer Institute (NCI), led by Harold Varmus, MD, presented to Congress a scientific framework that lays out important steps needed to make advances in small cell lung cancer, one of the most lethal forms of the disease. Read more...

TOPICS:

Roche Buying Seragon for Up to $1.7B

July 2, 2014 10:13 am | News | Comments

Roche Holding AG - the Basel, Switzerland-based pharmaceutical giant - said its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals Inc. for up to $1.725 billion in cash and contingency payments. Read more...

TOPICS:

OncoGenex Opens Enrollment for Lung Cancer Trial

July 2, 2014 8:30 am | News | Comments

OncoGenex announced initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced squamous cell lung cancer. Read more...      

TOPICS:

Approach IDs Mutations as Targets for Melanoma Immunotherapy

July 2, 2014 8:30 am | News | Comments

A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy. Read more...

TOPICS:

Quark Completes Trial of siRNA Compound in Kidney Transplant Patients

July 2, 2014 8:30 am | News | Comments

Quark Pharmaceuticals reported completion of a randomized, placebo-controlled multicenter Phase 2 trial of QPI-1002 for the prophylaxis of delayed graft function in ESRD dialysis-dependent patients undergoing deceased donor kidney transplantation. Read more...

TOPICS:

Sanofi Pasteur, CureVac to Develop mRNA-based Prophylactic Vaccine

July 2, 2014 8:30 am | News | Comments

CureVac and Sanofi Pasteur S.A. have executed an exclusive license agreement to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen. Read more...                       

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading